Thomas Barnard
Contributor since: 2009
Company: Business risk management, inc.
Articles
Generex Sees Way Forward With Long-Lasting COVID-19 Vaccine
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles
Interpretation Of Cytodyn's Mild-To-Moderate COVID-19 Results
Don't Forget Cytodyn's Other Prospects
CytoDyn May Be One Of The First Biotechs To Have A Drug That Helps Against Covid-19
A Basket Of Biotechs
Catastrophic Drop In Argentina Merval Calls To Mind John Templeton
Generex: Establishing A Value For Antigen Express' Dividend Shares
A Planned Spinoff Of Cancer Vaccines At Generex
The New Generex: Unlocking The Value
Tax Cuts, Hurricanes, Fires And A Good Jobs Report = Correction
What Would I Like In My Market Top Algorithm?
This Market Top Is A Strange Animal
CounterPath Contract Leverage (My Best Idea)
Nightmare For 401(K)ers: Assets May Go Down By 50%
Regression To The Mean
This Past Week In Telephone
It's A Good Time To Be A Consumer
With Ebola Looming, When Will The Defense Department Get Around To Generex?
From 1930 To 1995, The P/E Peak Was 24 In January 1966
Generex: A Stock Suitable Only For Its Officers And Directors Or Carl Icahn
Acquisition Target: CounterPath Corp.
Ben Bernanke Owns This Bubble, Baby
BlackBerry 10 And The Battle Of The Network Mobile Operating Systems
Generex: Research For Sale On The Cheap
No Hedge Funds Inside Banks
AT&T And Verizon Are Progressing In Transformation To Data Transmission Utilities
Remember When Cisco Had A Market Cap Of $500 Billion? What About Apple?
The Impact of Technology: Unemployment May Be More Stubborn This Time
Facebook Is to LinkedIn as Skype Is to Counterpath Corp.
Facebook Goes Asocial
Research In Motion Needs to Circle Back to the Enterprise